Zantac 75 sales reach $46 mil. in second quarter; OTC Tagamet sales $23 mil. worldwide.
This article was originally published in The Tan Sheet
ZANTAC 75 SECOND QUARTER SALES REACH $46 MIL. in the U.S., and the heartburn remedy has established a "strong number two position" in the OTC H2 antagonist market with a 35% share, Warner-Lambert said July 22. J&J/Merck's Pepcid AC continues as the category leader. Zantac 75 was introduced in the U.S. in late April 1996, and the company recently announced plans to launch the product in Canada, Australia and other European countries ("The Tan Sheet" April 21, p. 10)
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."